Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Recruiting × Topotecan × Clear all

Phase

Phase 3 15 Phase 2 4 Phase 1 4 Phase 2/3 2 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1

Status

Completed 20 Terminated 6 Unknown 2 Not yet recruiting 2 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 94 Cyclophosphamide 69 Carboplatin 55 fludarabine 50 Injections 50 Bevacizumab 43 Gemcitabine 37 venetoclax 34 Paclitaxel 34 Nivolumab 34 Cisplatin 33 Specimen Handling 32 Dexamethasone 32 Magnetic Resonance Spectroscopy 31 Docetaxel 30 Biopsy 28 toripalimab 22 Temozolomide 22 Pemetrexed 22 atezolizumab 21 Irinotecan 21 Azacitidine 21 Oxaliplatin 20 Fulvestrant 20 Capecitabine 20 abemaciclib 19 Rituximab 18 Fluorouracil 18 Radiotherapy 17 Cetuximab 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02813135 2026-01-16

ESMART

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡